{"id":"W2738407951","doi":"10.1200/jco.2017.35.15_suppl.9518","title":"A phase Ib/II dose-escalation study evaluating triple combination therapy with a BRAF (encorafenib), MEK (binimetinib), and CDK 4/6 (ribociclib) inhibitor in patients (Pts) with <i>BRAF V600</i>-mutant solid tumors and melanoma.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; MEK inhibitor; Response Evaluation Criteria in Solid Tumors; Oncology; Internal medicine; Melanoma; Palbociclib; Clinical endpoint; Pharmacokinetics; Pharmacology; Cancer; Phases of clinical research; Kinase; Cancer research; MAPK/ERK pathway; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001534346,0.001834855,0.001970365,0.0005996298,0.0004296739,0.0009812537,0.001059612,0.001227005,0.004765352],"category_scores_gemma":[0.0007584271,0.0009137684,0.001105135,0.0005595064,0.0009591674,0.001007014,0.0004371185,0.003371071,0.001189739],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001372452,"about_ca_system_score_gemma":0.001805416,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001467014,"about_ca_topic_score_gemma":0.003694488,"domain_scores_codex":[0.9995079,0.0002109494,0.00002540219,0.0001032075,0.00005233638,0.0001002292],"domain_scores_gemma":[0.9991691,0.00008719944,0.0001495084,0.00007331272,0.00004923537,0.0004717402],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6862575,0.1689652,0.007439463,0.0005927008,0.0013109,0.0002867638,0.0003985266,0.003336571,0.05641277,0.0003379172,0.004486175,0.07017551],"study_design_scores_gemma":[0.5579088,0.4236997,0.009872315,0.0000248046,0.0003338328,0.0003515062,0.0000621449,0.001618778,0.003359526,0.0002535354,0.002480585,0.00003455014],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9909062,0.0008336916,0.0007574004,0.0003423903,0.00008563139,0.00397286,0.001219746,0.0001197185,0.00176234],"genre_scores_gemma":[0.9847585,0.001006542,0.003198376,0.0008053157,0.00009973959,0.004496705,0.0026289,0.00004317816,0.002962782],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004765352,"threshold_uncertainty_score":0.01594174,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1003029350503233,"score_gpt":0.4806479685953801,"score_spread":0.3803450335450568,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}